早期妊娠因子（EPF）作为检测克罗米芬治疗女性亚临床胚胎丢失的标志物。

Early pregnancy factor (EPF) as a marker for detecting subclinical embryonic loss in clomiphene citrate-treated women.

作者信息

Shahani S K, Moniz C L, Gokral J S, Meherji P K

机构信息

Institute for Research in Reproduction, Bombay, India.

出版信息

Am J Reprod Immunol. 1995 May;33(5):350-3. doi: 10.1111/j.1600-0897.1995.tb00903.x.

DOI:10.1111/j.1600-0897.1995.tb00903.x

PMID:7576116

Abstract

PROBLEM

A discrepancy exists between the apparently normal ovulation and the pregnancy rates in women treated with clomiphene citrate (CC). Our previous studies have indicated that immuno-suppressive "early pregnancy factor" (EPF) is a novel marker to detect subclinical embryonic loss in infertile women.

METHOD

In the present study EPF was used as a marker to detect subclinical embryonic loss in women treated with CC with/without gonadotropins. In some of the women treated with CC, conception was assisted by artificial insemination with husband's semen (AIH).

RESULTS

Our results have indicated that fertilization occurred (EPF + ve) in 47.7% (52/109) of women treated with CC with/without gonadotropins; 13.46% (7/52) retained the fetus and continued pregnancy till full term, whereas 78.9% (41/52) did not retain the fetuses. In the group where after stimulation, conception was assisted by AIH, fertilization was observed in 38.24% (26/68), retention in 11.54% (3/26) but subclinical embryonic loss was observed in 80.8% (21/26) cases.

CONCLUSION

Thus, our results have indicated that subclinical embryonic loss may account for some of the discrepancy observed between the apparently normal ovulation and the pregnancy rates in women treated with clomiphene citrate.

摘要

问题

接受枸橼酸氯米芬（CC）治疗的女性，其排卵情况看似正常，但妊娠率却存在差异。我们之前的研究表明，免疫抑制性“早孕因子”（EPF）是检测不孕女性亚临床胚胎丢失的一种新标志物。

方法

在本研究中，EPF被用作标志物，以检测接受CC联合或不联合促性腺激素治疗的女性的亚临床胚胎丢失情况。在一些接受CC治疗的女性中，通过丈夫精液人工授精（AIH）辅助受孕。

结果

我们的结果表明，接受CC联合或不联合促性腺激素治疗的女性中，47.7%（52/109）发生了受精（EPF阳性）；13.46%（7/52）成功保胎并持续妊娠至足月，而78.9%（41/52）未能成功保胎。在刺激后通过AIH辅助受孕的组中，受精率为38.24%（26/68），保胎率为11.54%（3/26），但80.8%（21/26）的病例出现了亚临床胚胎丢失。